ZENITH高蛋白尿试验设计与基线特征:zibotentan/达格列净治疗CKD
ZENITH High Proteinuria是一项正在进行的随机双盲安慰剂对照3期试验,纳入UACR>700 mg/g或UPCR>1000 mg/g且eGFR≥20-<90 mL/min/1.73 m2的CKD患者。共筛选2910例,随机治疗1833例,主要疗效终点为24个月eGFR平均变化。
要点
- 纳入高蛋白尿CKD患者,UACR>700 mg/g或UPCR>1000 mg/g。
- 随机接受zibotentan/达格列净或安慰剂/达格列净治疗。
- 主要终点为24个月eGFR平均变化,结果预计2027年公布。
核心结论
- ZENITH High Proteinuria试验成功招募了CKD进展高风险人群,这些患者仍需要新疗法。
研究设计与样本
- 随机、双盲、安慰剂对照3期试验,纳入CKD患者伴或不伴2型糖尿病。
主要发现
- 基线平均年龄61岁,女性占28%。
- 基线平均eGFR为44.0(18.2)mL/min/1.73 m2。
- 基线UACR中位数1262(801-2097)mg/g,BNP中位数44(23-86)ng/L。
关键数值与推荐
- 入组标准:UACR>700 mg/g或UPCR>1000 mg/g,且eGFR≥20-<90 mL/min/1.73 m2。
- 随机1:1接受zibotentan/达格列净0.25/10 mg(eGFR<45)或0.75/10 mg(eGFR≥45)或安慰剂/达格列净,叠加标准治疗包括最大耐受RAS阻断。
- 主要疗效终点:基线至24个月eGFR平均变化。
- 次要疗效终点:至ESKD、eGFR持续下降≥40%或肾性死亡的复合终点时间。
临床怎么用
- 该试验针对高蛋白尿CKD患者,评估zibotentan/达格列净固定剂量组合的长期疗效与安全性。
局限性
- 本文仅报告设计与基线特征,疗效和安全性结果尚未公布。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A low dose of the selective endothelin A receptor antagonist zibotentan in combination with the sodium - glucose co-transporter 2 inhibitor (SGLT2i) dapagliflozin reduced urinary albumin-to-creatinine ratio (UACR) by ~30% compared to dapagliflozin alone in a phase 2b study without increasing the risk of fluid retention. These findings supported the design and conduct of the ZENITH High Proteinuria trial (NCT06087835) to assess the long-term efficacy and safety of a fixed-dose combination zibotentan/dapagliflozin in delaying the progression of chronic kidney disease (CKD). METHODS: ZENITH High Proteinuria is an ongoing randomized, double-blind, placebo-controlled phase 3 trial enrolling participants with CKD (defined as UACR >700 mg/g or urinary protein-to-creatinine ratio >1000 mg/g and estimated glomerular filtration rate [eGFR] ≥20-<90 mL/min/1.73 m2) with and without type 2 diabetes. Eligible participants were randomized 1:1 to zibotentan/dapagliflozin 0.25/10 mg (if eGFR<45 mL/min/1.73 m2)/0.75/10 mg (if eGFR ≥45 mL/min/1.73 m2) or placebo/dapagliflozin on top of standard of care, including maximum tolerated renin-angiotensin-system blockade. The primary efficacy outcome is the mean eGFR change from baseline to Month 24. Secondary efficacy outcomes include time to the composite of end-stage kidney disease, sustained ≥ 40% decrease in eGFR, or renal death. Adverse events are collected to assess safety. RESULTS: Participants were enrolled from November 2023 to November 2024 from 30 countries. Overall, 2910 patients were screened, of whom 1833 were randomized and treated. Mean age at baseline was 61 years and 28% were female. Mean (standard deviation) eGFR was 44.0 (18.2) mL/min/1.73 m2, median (interquartile range) UACR was 1262 (801-2097) mg/g, and median (interquartile range) B-type natriuretic peptide was 44 (23-86) ng/L. CONCLUSION: To evaluate the effect of zibotentan and dapagliflozin combination therapy, the ZENITH High Proteinuria study has successfully recruited a population at high risk of CKD progression for whom novel therapies remain necessary. Results are expected in 2027.
引用
- Heerspink HJL, Arnott C, Barratt J, et al. Design and baseline characteristics of the ZENITH high proteinuria trial testing zibotentan/dapagliflozin efficacy in CKD. Nephrol Dial Transplant. 2026. PMID: 42550497. doi:10.1093/ndt/gfag172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。